X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (298) 298
postremission therapy (252) 252
hematology (246) 246
adult (211) 211
middle aged (209) 209
female (203) 203
male (203) 203
acute myelogenous leukemia (201) 201
oncology (186) 186
index medicus (162) 162
adolescent (145) 145
remission induction (135) 135
treatment outcome (130) 130
aged (121) 121
antineoplastic combined chemotherapy protocols - therapeutic use (112) 112
leukemia, myeloid, acute - therapy (110) 110
bone-marrow-transplantation (109) 109
acute myeloid-leukemia (106) 106
acute myeloid leukemia (105) 105
leukemia, myeloid, acute - mortality (98) 98
chemotherapy (96) 96
disease-free survival (96) 96
transplantation (95) 95
intensive chemotherapy (88) 88
leukemia, myeloid, acute - drug therapy (84) 84
postremission chemotherapy (83) 83
prognosis (83) 83
stem-cell transplantation (82) 82
high-dose cytarabine (75) 75
acute disease (74) 74
survival analysis (74) 74
aml (73) 73
cytarabine - administration & dosage (73) 73
transplantation, homologous (72) 72
acute nonlymphocytic leukemia (71) 71
retrospective studies (65) 65
young adult (65) 65
1st complete remission (60) 60
hematopoietic stem cell transplantation (58) 58
adults (56) 56
leukemia, myeloid, acute - genetics (56) 56
survival rate (54) 54
cancer (52) 52
recurrence (51) 51
leukemia, myeloid - drug therapy (49) 49
1st remission (48) 48
stem cells (48) 48
transplantation, autologous (48) 48
bone-marrow transplantation (47) 47
risk factors (47) 47
immunology (46) 46
cytosine-arabinoside (45) 45
hematopoietic stem cells (44) 44
follow-up studies (43) 43
adult patients (42) 42
daunorubicin (42) 42
group-b (42) 42
colony-stimulating factor (40) 40
cytarabine - therapeutic use (39) 39
cytogenetics (38) 38
aged, 80 and over (37) 37
leukemia, myeloid - therapy (36) 36
survival (36) 36
bone marrow transplantation (34) 34
cytarabine (34) 34
hematology, oncology and palliative medicine (34) 34
leukemia (34) 34
antineoplastic agents - therapeutic use (33) 33
combined modality therapy (33) 33
older patients (33) 33
remission (33) 33
research (33) 33
therapy (32) 32
age factors (31) 31
hematopoietic stem cell transplantation - methods (31) 31
acute myeloblastic-leukemia (30) 30
leukemia, myeloid - mortality (30) 30
trial (30) 30
relapse (29) 29
antineoplastic combined chemotherapy protocols - administration & dosage (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
child (28) 28
daunorubicin - administration & dosage (28) 28
minimal residual disease (28) 28
induction (27) 27
acute myelocytic-leukemia (26) 26
analysis (26) 26
consolidation chemotherapy (26) 26
consolidation therapy (26) 26
leukemia, myeloid, acute - pathology (25) 25
prospective studies (25) 25
karyotyping (24) 24
acute lymphoblastic-leukemia (23) 23
acute promyelocytic leukemia (23) 23
etoposide - administration & dosage (23) 23
medicine, general & internal (23) 23
bone marrow (22) 22
care and treatment (22) 22
consolidation (22) 22
drug administration schedule (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 219 - 228
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2017, Volume 92, Issue 10, pp. E567 - E574
The aim of this study was to evaluate the efficacy and feasibility of intensified consolidation therapy employing fludarabine and ARA-C in cycle 1 and... 
COLONY-STIMULATING FACTOR | INDUCTION CHEMOTHERAPY | DOSE CYTARABINE | ACUTE MYELOGENOUS LEUKEMIA | DOUBLE-BLIND | POSTREMISSION CHEMOTHERAPY | RANDOMIZED-TRIAL | PLACEBO-CONTROLLED TRIAL | REMISSION-INDUCTION | HEMATOLOGY | ELDERLY-PATIENTS | Recombinant Proteins - therapeutic use | Neutropenia - epidemiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Consolidation Chemotherapy - methods | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Hospitalization - statistics & numerical data | Cytarabine - adverse effects | Recombinant Proteins - adverse effects | Filgrastim | Feasibility Studies | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Neutropenia - chemically induced | Granulocyte Colony-Stimulating Factor - adverse effects | Drug Administration Schedule | Polyethylene Glycols | Vidarabine - adverse effects | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Cytarabine - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Vidarabine - administration & dosage | Consolidation Chemotherapy - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 01/2014, Volume 99, Issue 1, pp. 46 - 53
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2011, Volume 17, Issue 12, pp. 1796 - 1803
Journal Article
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 2012, Volume 91, Issue 6, pp. 825 - 835
Journal Article
Hematological Oncology, ISSN 0278-0232, 03/2014, Volume 32, Issue 1, pp. 1 - 9
Acute myeloid leukaemia (AML) is the second more frequent hematologic malignancy in developed countries and primarily affects older adults with a median age at... 
hypomethylating agents | older patients | acute myeloid leukaemia | chemotherapy | Older patients | Acute myeloid leukaemia | Chemotherapy | Hypomethylating agents | 1ST-LINE TREATMENT | GEMTUZUMAB OZOGAMICIN | INDUCTION CHEMOTHERAPY | POSTREMISSION TREATMENT | RISK MYELODYSPLASTIC SYNDROME | PHASE-II TRIAL | ONCOLOGY | LOW-DOSE CYTARABINE | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ELDERLY-PATIENTS | Prognosis | Age Factors | DNA, Neoplasm - metabolism | Humans | Middle Aged | Neoplasm Proteins - antagonists & inhibitors | Consolidation Chemotherapy | Molecular Targeted Therapy | Antimetabolites, Antineoplastic - administration & dosage | Enzyme Inhibitors - administration & dosage | Multicenter Studies as Topic | Leukemia, Myeloid, Acute - drug therapy | Antimetabolites, Antineoplastic - pharmacology | Leukemia, Myeloid, Acute - surgery | Azacitidine - administration & dosage | DNA-Cytosine Methylases - antagonists & inhibitors | Comorbidity | Enzyme Inhibitors - pharmacology | Hematopoietic Stem Cell Transplantation | Azacitidine - analogs & derivatives | Survival Rate | Treatment Outcome | Combined Modality Therapy | Enzyme Inhibitors - therapeutic use | Remission Induction | Randomized Controlled Trials as Topic | Azacitidine - pharmacology | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | DNA Methylation - drug effects | Leukemia, Myeloid, Acute - genetics | Aged patients | Drug therapy | Cancer | Index Medicus
Journal Article